Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys

DSpace/Manakin Repository

Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys

Citable link to this page

 

 
Title: Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys
Author: Borducchi, Erica N.; Cabral, Crystal; Stephenson, Kathryn E.; Liu, Jinyan; Abbink, Peter; Ng’ang’a, David; Nkolola, Joseph P.; Brinkman, Amanda L.; Peter, Lauren; Lee, Benjamin C.; Jimenez, Jessica; Jetton, David; Mondesir, Jade; Mojta, Shanell; Chandrashekar, Abishek; Molloy, Katherine; Alter, Galit; Gerold, Jeff M.; Hill, Alison L.; Lewis, Mark G.; Pau, Maria G.; Schuitemaker, Hanneke; Hesselgesser, Joseph; Geleziunas, Romas; Kim, Jerome H.; Robb, Merlin L.; Michael, Nelson L.; Barouch, Dan H.

Note: Order does not necessarily reflect citation order of authors.

Citation: Borducchi, E. N., C. Cabral, K. E. Stephenson, J. Liu, P. Abbink, D. Ng’ang’a, J. P. Nkolola, et al. 2016. “Ad26/MVA Therapeutic Vaccination with TLR7 Stimulation in SIV-Infected Rhesus Monkeys.” Nature 540 (7632): 284-287. doi:10.1038/nature20583. http://dx.doi.org/10.1038/nature20583.
Full Text & Related Files:
Abstract: The development of immunologic interventions that can target the viral reservoir in HIV-1-infected individuals is a major goal of the HIV-1 cure field1,2. However, little evidence exists that the viral reservoir can be sufficiently targeted to improve virologic control following discontinuation of antiretroviral therapy (ART). Here we show that Ad26/MVA3,4 therapeutic vaccination with toll-like receptor 7 (TLR7) stimulation improves virologic control and delays viral rebound following ART discontinuation in SIV-infected rhesus monkeys that initiated ART during acute infection. Ad26/MVA therapeutic vaccination resulted in a dramatic increase in the magnitude and breadth of SIV-specific cellular immune responses in virologically suppressed, SIV-infected monkeys. TLR7 agonist administration led to innate immune stimulation and cellular immune activation. The combination of Ad26/MVA vaccination and TLR7 stimulation resulted in decreased levels of viral DNA in lymph nodes and peripheral blood, as well as improved virologic control and delayed viral rebound following ART discontinuation. Cellular immune breadth correlated inversely with setpoint viral loads and correlated directly with time to viral rebound. These data demonstrate the potential of therapeutic vaccination with innate immune stimulation as a strategy aimed at an HIV-1 functional cure.
Published Version: doi:10.1038/nature20583
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5145754/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:33029967
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters